GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Zura Bio Limited
Shares of Zura Bio, a biotech focused on immunology, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma immune
Zura Bio Limited is a biopharmaceutical company developing drugs for the treatment of immune and inflammatory diseases. We classify it in the "Pharmaceuticals (Immunology)" segment, as its research is aimed at modulating the body's immune response. The graph below shows the dynamics of this complex and promising area of medicine.
Broad Market Index - GURU.Markets
Zura Bio is a biopharmaceutical company developing drugs to treat immunological and inflammatory diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
ZURA - Daily change in the company's share price Zura Bio Limited
For Zura Bio Limited, a biopharmaceutical company, the daily price change is a measure of the high volatility typical of the sector. This metric reflects the market's reaction to drug development news and is critical to the risk assessment formulas for innovative companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Zura Bio Limited is a biotech company. This chart highlights the extreme volatility of the sector. Comparing this to Zura's performance, which is dependent on clinical trial results, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Zura Bio is a biotech company focused on immunology. Like many companies in the sector, its shares are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Zura Bio Limited
Zura Bio Limited's year-over-year performance is a story of developing drugs for the treatment of immune diseases. Its market capitalization over the past 12 months depends entirely on progress in clinical trials. Each successful step confirms the potential of its scientific platform and brings the company closer to the creation of new treatments for patients with serious diseases.
Annual dynamics of market capitalization of the market segment - Pharma immune
Zura Bio Limited is a clinical-stage biotechnology company focused on developing drugs for the treatment of immunological diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zura Bio is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Zura Bio Limited
Zura Bio is a clinical-stage biotech focused on immunology. Its monthly performance is entirely dependent on development news. The chart reflects the sector's inherent high volatility: positive trial data triggers a sharp rise, while any delays or setbacks trigger an equally sharp decline.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Zura Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of immune and inflammatory diseases. Their success depends on the results of clinical trials. The chart below shows the overall dynamics in the immunology sector, one of the most active and competitive in the pharmaceutical industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Zura Bio move in sync with it, or do its R&D developments create a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Zura Bio Limited
The weekly performance of Zura Bio, a biotech company specializing in immunology, reflects the search for new treatments for autoimmune diseases. Its stock price is responding to progress in clinical trials of its drugs, which could offer new solutions for patients.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Zura Bio is a biotech company focused on immunology. Like many companies in the sector, its value is determined by the potential of its drugs and clinical trial data. The chart below shows whether Zura's share price movement is driven by company news or reflects a general investor reaction to industry events.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Zura Bio is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Zura Bio is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
ZURA - Market capitalization of the company Zura Bio Limited
Zura Bio's market capitalization chart tells the story of a biotech company founded to develop a portfolio of immunology assets. Its volatility reflects the market's assessment of the potential of its drug candidates for treating various autoimmune diseases. Its trajectory tells the story of the company's growth through licensing and clinical development.
ZURA - Share of the company's market capitalization Zura Bio Limited within the market segment - Pharma immune
Zura Bio is a clinical-stage biotech company focused on developing drugs to treat immune and inflammatory diseases. Its market capitalization reflects the market's assessment of the potential of its pipeline. The chart shows its position among other biotechs operating in this competitive field.
Market capitalization of the market segment - Pharma immune
Zura Bio is a clinical-stage biotech company focused on immunology. The chart below shows the overall market capitalization of this sector. Its volatile dynamics reflect the promise and risks associated with the long and expensive process of drug discovery.
Market capitalization of all companies included in a broad market index - GURU.Markets
Zura Bio is a clinical-stage biotech company working in the field of immunology. Its market cap reflects investors' faith in the science behind its drug candidates. Its volatility on the overall chart reflects how the market assesses the chances of success in the long and expensive race for a new drug.
Book value capitalization of the company, segment and market as a whole
ZURA - Book value capitalization of the company Zura Bio Limited
Zura Bio's balance sheet represents its capital earmarked for clinical trials of drugs targeting immunological and inflammatory diseases. This provides a tangible, scientific foundation for discovering new therapeutic solutions. How has this young biotech asset evolved? The chart below shows its dynamics.
ZURA - Share of the company's book capitalization Zura Bio Limited within the market segment - Pharma immune
Zura Bio is a biopharmaceutical company developing treatments for immune diseases, which requires research laboratories. The chart shows the share of these knowledge-intensive tangible assets, reflecting the physical foundation of its scientific activities.
Market segment balance sheet capitalization - Pharma immune
Zura Bio is a biotech company focused on immunology. At the research stage, its main asset is its scientific potential. The book value chart shows how "light" its capital base is compared to big pharma.
Book value of all companies included in the broad market index - GURU.Markets
Zura Bio Limited is a biotechnology company focused on treating immune diseases. Its book value is derived from its clinical trial capital and its portfolio of licensed assets. The chart shows the material foundation upon which the development of new therapeutic approaches is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Zura Bio Limited
Zura Bio's balance sheet is capital. Its market price is a bet on the success of its clinical immunology programs. The chart shows the "hope factor," which depends entirely on investors' faith in its scientific potential, not on its current assets.
Market to book capitalization ratio in a market segment - Pharma immune
Zura Bio is a biotech company focused on immunology. Like other clinical-stage companies, its value is determined by the potential of its scientific developments. The chart shows investors' bets on the future success of its drugs, rather than on its current assets.
Market to book capitalization ratio for the market as a whole
Zura Bio is a clinical-stage biotech developing drugs to treat immune diseases. Its value is entirely dependent on the success of its research. This chart shows the overall market valuation, but how do investors evaluate the potential of another company exploring new treatments for autoimmune disorders?
Debts of the company, segment and market as a whole
ZURA - Company debts Zura Bio Limited
Zura Bio, a clinical-stage biotech company focused on immunology, reflects its financial strategy for survival and growth: raising capital to finance expensive and lengthy clinical trials of its drugs, a high-risk investment in the future of medicine.
Market segment debts - Pharma immune
Zura Bio is a clinical-stage biotech company focused on immunology. Funding is key to advancing its candidates through the expensive phases of clinical trials. This chart shows how the company secures resources for long-term research in this complex field.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Zura Bio Limited
Zura Bio is a biopharmaceutical company focused on immunology. This chart is vital for assessing its financial health. It shows how reliant the company is on debt financing to conduct expensive clinical trials. It's a classic biotech story: debt fueling high-risk science.
Market segment debt to market segment book capitalization - Pharma immune
Zura Bio is a clinical-stage biotech company focused on immunology and inflammatory diseases. This chart shows the collective debt burden in the immunopharmaceuticals sector. It helps understand how the industry as a whole finances its long-term and risky clinical research.
Debt to book value of all companies in the market
Zura Bio is a biopharmaceutical company focused on immunology. Being in clinical development, it relies entirely on investor funding. This chart, reflecting the debt burden in a traditional economy, underscores that Zura Bio's business is a venture capital bet on science, not on leveraging.
P/E of the company, segment and market as a whole
P/E - Zura Bio Limited
This chart for Zura Bio Limited, a biopharmaceutical company, shows how investors value its research and development. As with many companies in this industry at the research stage, this metric can be irrelevant. It reflects not current profits but rather the company's expectations for the future commercial success of its immunology drugs.
P/E of the market segment - Pharma immune
Immunology, where Zura Bio develops new drugs, is a promising field. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Zura is valued as a research project, and its value depends on the success of clinical trials of its drugs for the treatment of autoimmune and inflammatory diseases.
P/E of the market as a whole
Zura Bio Limited is a clinical-stage biotech company focused on developing drugs to treat immune and inflammatory diseases. Its success depends on the results of clinical trials. This chart, reflecting overall investor risk appetite, shows how willing the market is to fund Zura Bio's research in the hopes of developing a new drug.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Zura Bio Limited
Zura Bio is a clinical-stage biotech company focused on immunology. This chart reflects investors' speculative expectations for the success of its clinical programs. The trend represents the market's assessment of the likelihood of approval of its drugs for various autoimmune diseases.
%20P%2FE%20Zura%20Bio%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Zura-Bio-Limited&v=1772649077353 "Chart of the company's future (projected) P/E Zura Bio Limited")
Future (projected) P/E of the market segment - Pharma immune
Zura Bio is a clinical-stage biotech company focused on developing drugs to treat immune and inflammatory diseases. This chart shows profitability expectations for the sector. It allows investors to assess the scientific potential of its developments and their chances of success in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772649077389 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Zura Bio Limited is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of immune and inflammatory diseases. This chart shows investor risk appetite. For a company with a development pipeline in immunology, it reflects the market's willingness to finance long-term and risky research projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772649077418 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Zura Bio Limited
Zura Bio Limited is a clinical-stage biotechnology company focused on immunological and inflammatory diseases. The financial metrics presented here reflect the costs of developing its therapeutic candidates. This chart illustrates the cost of research into new treatments for complex autoimmune disorders.
Profit of companies in the market segment - Pharma immune
Zura Bio is a clinical-stage biotech company focused on developing drugs to treat immune and inflammatory diseases. Its success depends on clinical trial results and regulatory approval. This chart illustrates the high risk and potential reward in the immunology sector, where a single successful drug can generate billions.
Overall market profit
Zura Bio is a clinical-stage biotech company focused on immunological diseases. Its future depends entirely on success in clinical trials and raising capital. The overall economic situation, reflected in this chart, directly impacts the investment climate and investor willingness to fund such long-term and risky scientific projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Zura Bio Limited
Zura Bio is a clinical-stage biotech company specializing in immunology. The profit/loss projections in this chart reflect high R&D costs. The curve's dynamics reflect analyst expectations for clinical trial results.
%20profit%20of%20the%20company%20Zura%20Bio%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Zura-Bio-Limited&v=1772649077467 "Graph of future (projected) profit of the company Zura Bio Limited")
Future (predicted) profit of companies in the market segment - Pharma immune
Zura Bio Limited is a biopharmaceutical company developing drugs for the treatment of immune and inflammatory diseases. The company is likely advancing its clinical programs toward commercialization. This chart shows the revenue forecast for the immune pharmaceutical sector, providing context for assessing the potential of Zura Bio's pipeline relative to the industry as a whole.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772649077480 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Zura Bio is a biotech company focused on immunology. Like other clinical-stage companies, its value depends on the potential of its developments. This graph, reflecting overall market sentiment, impacts the availability of capital needed to fund lengthy and expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772649077487 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Zura Bio Limited
Zura Bio is a biotech company developing drugs to treat immune and inflammatory diseases. This chart reflects investor expectations for its clinical programs. Revenue estimates (from potential partnerships) are a bet on the success of its pipeline candidates.
P/S market segment - Pharma immune
Zura Bio Limited is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of immune and inflammatory diseases. This chart shows the industry average market capitalization-to-revenue ratio. It reflects investor expectations for Zura Bio's clinical programs and the potential of its drugs.
P/S of the market as a whole
Zura Bio is a clinical-stage biotech focused on developing drugs for the treatment of immune and inflammatory diseases. The company is developing a portfolio of assets with diverse mechanisms of action. This chart helps understand how the market values biotech companies targeting large but competitive therapeutic areas.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Zura Bio Limited
Zura Bio is a clinical-stage biotech company focused on treating immune and inflammatory diseases. This chart shows its valuation relative to future, currently hypothetical, sales. It measures investor expectations for the success of its clinical programs and the potential of its drug candidates.
%20P%2FS%20Zura%20Bio%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Zura-Bio-Limited&v=1772649077544 "The graph of the company's future (projected) P/S Zura Bio Limited")
Future (projected) P/S of the market segment - Pharma immune
Zura Bio is a clinical-stage biotechnology company focused on developing drugs for the treatment of immune and inflammatory diseases. Its future depends on the success of clinical trials. This metric reflects investor expectations for its scientific pipeline and potential future revenue compared to other immunopharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772649077577 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Zura Bio is a clinical-stage biotech company focused on immunology. Its value is determined by the potential of its scientific developments. This graph of overall market expectations for Zura Bio is not a direct driver. The company's success depends on clinical trial results, not short-term economic cycles, and can create its own trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772649077604 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Zura Bio Limited
This chart illustrates the financial path of a clinical-stage biotech company. For Zura Bio, which focuses on treating immunological diseases, it reflects the funding and partnerships needed to advance its pipeline of drug candidates through clinical trials.
Sales of companies in the market segment - Pharma immune
Zura Bio Limited is a clinical-stage biotechnology company focused on developing drugs to treat immune and inflammatory diseases. Its success depends on trial results. This chart shows revenue in immunology, and a potential breakthrough for Zura Bio could offer new therapeutic options and expand the overall market.
Overall market sales
Zura Bio is a clinical-stage biotechnology company focused on developing drugs to treat immune diseases. Its success depends on research results and regulatory approval. The company is part of an innovative healthcare ecosystem that is developing new treatments and shaping future pharmaceutical markets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Zura Bio Limited
Zura Bio is a biotechnology company developing drugs to treat immune and inflammatory diseases. Its future sales forecast depends on the results of clinical trials and the potential commercialization of new therapies.
%20sales%20of%20the%20company%20Zura%20Bio%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Zura-Bio-Limited&v=1772649077733 "Schedule of future (projected) sales of the company Zura Bio Limited")
Future (projected) sales of companies in the market segment - Pharma immune
Zura Bio Limited is a biotechnology company focused on clinical research in immunology. This forecast for the immune pharmaceutical sector highlights general scientific and investment trends. This chart provides context, allowing one to assess how Zura Bio's specific developments may stand out from the general expectations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772649077769 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Zura Bio is a clinical-stage biotech company focused on immunology. Its prospects depend entirely on the success of clinical trials. The overall economic situation, reflected in this chart, does not affect the need for treatment, but it does shape the overall investment climate and influence the cost of raising capital for research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772649077790 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Zura Bio Limited
Zura Bio is a clinical-stage biotech company focused on developing drugs to treat immune diseases. Its financial performance reflects its high R&D expenditures. This chart shows the company's investment in its research portfolio to develop new treatments, not its current profits.
Market segment marginality - Pharma immune
Zura Bio Limited is a clinical-stage biotechnology company developing drugs for the treatment of immune and inflammatory diseases. Its financial metrics reflect research and development expenses. This chart provides an overview of the company's operating model and cost structure compared to other companies in the immunology field.
Market marginality as a whole
Zura Bio Limited is a clinical-stage biotechnology company focused on immunology. This chart shows overall profitability. In this context, Zura Bio is a venture capital bet on science. The company's financial metrics reflect research expenditures, and its future profitability depends entirely on the success of its drugs in clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Zura Bio Limited
Zura Bio is a clinical-stage biotech company focused on immunology and inflammatory diseases. Its small team consists of experienced drug developers. The progress on this graph will reflect key development milestones, with staff expansion following successful research results and new funding.
Share of the company's employees Zura Bio Limited within the market segment - Pharma immune
Zura Bio is a clinical-stage biotechnology company focused on developing drugs for the treatment of immune and inflammatory diseases. This chart illustrates its scientific potential. It reflects the proportion of immunologist and clinical research scientists working on new therapeutic approaches in this field that Zura Bio attracts.
Number of employees in the market segment - Pharma immune
Zura Bio is a biotech company focused on immunology. This graph for the biopharmaceutical sector demonstrates that its development is driven by scientific breakthroughs. The growth of the research team here signifies progress in understanding the complex mechanisms of the immune system to develop new treatments for autoimmune and inflammatory diseases.
Number of employees in the market as a whole
Zura Bio Limited is a biotech company working in the field of immunology. For companies like these, full-time work schedules are irrelevant during the research phase. Their world is labs, clinical trials, and scientific publications. Staff expansion doesn't happen gradually, but rather in spurts, following positive data and a new round of funding.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Zura Bio Limited (ZURA)
Zura Bio is a biotech company developing drugs to treat immune and inflammatory diseases. Its value lies in the potential of its scientific research. This chart shows how investors value intellectual capital in the pharmaceutical industry. The high market capitalization per employee suggests that the market is pricing in the future success of its drugs.
%20of%20the%20company%20Zura%20Bio%20Limited%20(ZURA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Zura-Bio-Limited-ZURA&v=1772649078566 "Chart of market capitalization per employee (in thousands of dollars) of the company Zura Bio Limited (ZURA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Zura Bio is a biopharmaceutical company focused on immunology. Like many development-stage biotechs, its value is determined by its research prospects, not its current operations. This chart clearly demonstrates the high premium the market places on the intellectual capital of the team working on developing future drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772649078592 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Zura Bio is a clinical-stage biopharmaceutical company focused on immunology. This chart reflects the high valuation per employee typical of biotech, where a company's value is determined entirely by its research potential, not current revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772649078604 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Zura Bio Limited (ZURA)
Zura Bio is a biotech company focused on immunology and inflammatory diseases. They develop drugs to treat conditions where the immune system attacks the body. They are an R&D company. This metric is likely negative. It reflects how much the company invests in each scientist and doctor to advance their candidates through clinical trials.
%20Chart%20Zura%20Bio%20Limited%20(ZURA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Zura-Bio-Limited-ZURA&v=1772649078608 "Company Profit Per Employee (in thousands of dollars) Chart Zura Bio Limited (ZURA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Zura Bio (ZURA) is a clinical-stage biotech company focused on immunology. For them, this industry-standard chart is a distant goal. At the R&D stage, profitability is negative. Success for ZURA would mean that their scientific team has created a drug that will deliver a financial return many times higher than the current average.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772649078614 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Zura Bio Limited is a biotechnology company working in the field of immunology. Being in the clinical stage, the company has no commercial products, and its entire activity is R&D. This indicator, being negative, reflects solely the "cost" of the scientific team that must bring developments to approval and market launch.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772649078635 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Zura Bio Limited (ZURA)
Zura Bio is a clinical-stage biotech company focused on immunology. This chart reflects its current status as an R&D organization. Lack of revenue is normal. In the future, this metric will be key to assessing the commercial success of its drugs, demonstrating revenue per employee once they reach market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Zura-Bio-Limited-ZURA&v=1772649078665 "Sales chart per company employee Zura Bio Limited (ZURA)")
Sales per employee in the market segment - Pharma immune
Zura Bio is a biotech company developing drugs to treat immune and inflammatory diseases. At the clinical trial stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee, which is critical for funding expensive R&D.
Sales per employee for the market as a whole
Zura Bio is a clinical-stage biotech company focused on immunology and inflammatory diseases. It's a 100% R&D company. This chart shows revenue per employee. Predictably, it's zero. It emphasizes that the company doesn't sell products, but rather invests in lengthy and expensive clinical trials, where its research staff creates future value.
Short shares by company, segment and market as a whole
Shares shorted by company Zura Bio Limited (ZURA)
Zura Bio Limited is a clinical-stage biotech developing drugs to treat immune and inflammatory diseases. This chart shows bearish bets. Bears are betting on clinical trial failure, a common high risk for biotech companies that don't yet have approved products or revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Zura-Bio-Limited-ZURA&v=1772649078736 "Short Shares Chart for the Company Zura Bio Limited (ZURA)")
Shares shorted by market segment - Pharma immune
Zura Bio is a biotech company specializing in developing drugs to treat immune and inflammatory diseases. This chart shows overall short positions in the biotech sector. A high reading reflects general market skepticism about the sector, possibly due to fears of research failures or funding issues.
Shares shorted by the overall market
Zura Bio (ZURA) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies in droves that need refinancing for R&D, and ZURA finds itself at the center of the sell-off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Zura Bio Limited (ZURA)
Zura Bio is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can soar above 70 on positive R&D data, but this is at risk of a correction. Oversold territory (<30) often reflects setbacks, funding concerns, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Zura-Bio-Limited-ZURA&v=1772649078808 "RSI 14 indicator chart for the company's stock Zura Bio Limited (ZURA)")
RSI 14 Market Segment - Pharma immune
Zura Bio (ZURA) is a biotech company focused on immune diseases (autoimmune diseases). The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether ZURA's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
For Zura Bio, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZURA (Zura Bio Limited)
Zura Bio is a biotech company developing drugs for the treatment of immunological and inflammatory diseases. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet that the company's R&D portfolio, acquired through acquisitions, will prove successful.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZURA-Zura-Bio-Limited&v=1772649078853 "A chart showing analyst consensus forecasts for the expected stock price. ZURA (Zura Bio Limited)")
The difference between the consensus estimate and the actual stock price ZURA (Zura Bio Limited)
Zura Bio (ZURA) is a clinical-stage biotech developing drugs for the treatment of autoimmune and inflammatory diseases. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZURA-Zura-Bio-Limited&v=1772649078863 "A chart showing the difference between the consensus forecast and the actual stock price. ZURA (Zura Bio Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Zura Bio is a biotech company developing drugs to treat autoimmune and inflammatory diseases. This chart shows analysts' overall expectations for the entire immune pharma sector. It reflects whether experts believe in R&D breakthroughs in this complex area of medicine or consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Zura Bio Limited is a biotechnology company specializing in developing drugs to treat immune and inflammatory diseases. This chart shows overall risk appetite. For Zura, a high-risk clinical-stage company, overall market optimism is critical to raising the capital needed to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Zura Bio Limited
Zura Bio is a clinical-stage biotech company focused on immunology. They develop drugs (antibodies) targeting key signaling pathways that cause inflammatory and autoimmune diseases. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative estimate of their R&D progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Zura Bio is a clinical-stage biotech company developing drugs to treat immunological and inflammatory diseases. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Zura Bio's performance compares to the industry average for companies seeking disruption.
The AKIM Index for the overall market
Zura Bio is a biotech company developing immunology drugs (licensed from Pfizer/Lilly) for the treatment of autoimmune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this asset refinement strategy compares to overall economic trends and interest in immunology.
